Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > IBCG - New activity in the BCG Unresponsive Space

<< Previous

Bullboard Posts

Next >>

Comment by LaserStock29on May 31, 2022 3:51pm

175 Views

Post# 34721070

RE:RE:IBCG - New activity in the BCG Unresponsive Space

Irrelevant question the 2nd dose concern is safety to said organ tissue to unlock big pharma being able to see photodynamic as a matured science. Aka the window for multiple treatments. In fact in a twisted logic you would want every patient to be PR after 1 and CR after 2. Lol

Rumpl3StiltSkin wrote: Will be interesting to see what TLT's long term cystectomy-free rate is after 2 treatments. They have to go through 11 BCG-combo treatments? Each treatment is a mini ordeal, no?

ScienceFirst wrote:

ImmuneBio has a problem; it depends on BCG availability.

Coming from the highest instance in the bladder arena; IBCG (International Bladder Cancer Group).

https://www.ibcg.info/newsletter

New activity in the BCG Unresponsive Space

Despite its success, many patients with high-risk non-muscle-invasive bladder cancer treated with BCG eventually develop BCG-unresponsive disease. Bladder sparing therapeutic options for these patients remains limited. Two studies were reported in the BCG Unresponsive space at ASCO-GU 2022. In a phase 3 trial assessing combination therapy using IL-15RαFc superagonist N-803 (Anktiva) and BCG, Dr. Sam Chang reported complete response rates of 71% (95% CI 60.1 – 80.5%) at any time, with median duration of response of 24.1mo and a 55% probability of maintaining response for ≥18mo in a cohort of 83 patients with CIS containing BCG Unresponsive NMIBC. The cystectomy-free rate in responders was 93%. Among 77 patients with papillary only disease, the 12-month disease free rate was 57% and 53% at 18-month. Similarly, a 95% cystectomy-free rate was seen at 20.7-month median follow-up. The treatment combination was also well tolerated, with no treatment-related grade 4/5 adverse events, and no immune-related adverse events. Despite these exciting results, treatment efficacy does depend on combination with BCG, and administration of this combination will be impacted by the ongoing global BCG shortage.